BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27103124)

  • 21. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers.
    Connarn JN; Flowers S; Kelly M; Luo R; Ward KM; Harrington G; Moncion I; Kamali M; McInnis M; Feng MR; Ellingrod V; Babiskin A; Zhang X; Sun D
    AAPS J; 2017 Sep; 19(5):1513-1522. PubMed ID: 28685396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation of a modified-release pregabalin tablet using hot-melt coating with glyceryl behenate.
    Jeong KH; Woo HS; Kim CJ; Lee KH; Jeon JY; Lee SY; Kang JH; Lee S; Choi YW
    Int J Pharm; 2015 Nov; 495(1):1-8. PubMed ID: 26315121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formulation, Characterization and
    Patel P; Barot T; Kulkarni P
    Curr Drug Deliv; 2020; 17(3):257-268. PubMed ID: 32056523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.
    Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia.
    Lukacsko P; Walters EJ; Cullen EI; Niecestro R; Friedhoff LT
    Curr Med Res Opin; 2004 Jan; 20(1):13-8. PubMed ID: 14741066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Franke RM; Morton T; Devarakonda K
    Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
    Ahmad M; Pervaiz F
    Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of biopolymers based interpenetrating polymeric network of capecitabine: A drug delivery vehicle to extend the release of the model drug.
    Upadhyay M; Adena SKR; Vardhan H; Yadav SK; Mishra B
    Int J Biol Macromol; 2018 Aug; 115():907-919. PubMed ID: 29705110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
    Patrick J; Dillaha L; Armas D; Sessa WC
    Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.
    Zhao Q; Janssens L; Verhaeghe T; Brashear HR; Truyen L
    Curr Med Res Opin; 2005 Oct; 21(10):1547-54. PubMed ID: 16238894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.
    Devarakonda K; Kostenbader K; Zheng Y; Montgomery JB; Barrett T; Young JL; Webster LR
    Postgrad Med; 2015 Jan; 127(1):13-21. PubMed ID: 25584931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation.
    Liu DJ; Collaku A; Youngberg SP
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):172-81. PubMed ID: 25500485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.